MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329404 | Name: Alacepril

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alacepril, also known as Cetapril and DU-1219, is an angiotensin-converting enzyme inhibitor and is commonly used as an antihypertensive.

Chemical Structure

Alacepril
Alacepril
CAS#74258-86-9

Theoretical Analysis

MedKoo Cat#: 329404

Name: Alacepril

CAS#: 74258-86-9

Chemical Formula: C20H26N2O5S

Exact Mass: 406.1562

Molecular Weight: 406.50

Elemental Analysis: C, 59.10; H, 6.45; N, 6.89; O, 19.68; S, 7.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Alacepril; DU-1219; DU 1219; DU1219; Cetapril; Alaceprilum
IUPAC/Chemical Name
(3-(acetylthio)-2-methylpropanoyl)-L-prolyl-L-phenylalanine
InChi Key
FHHHOYXPRDYHEZ-LMARGRMVSA-N
InChi Code
InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13?,16-,17-/m0/s1
SMILES Code
O=C(O)[C@H](CC1=CC=CC=C1)NC([C@H]2N(C(C(C)CSC(C)=O)=O)CCC2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 406.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sakatani A, Miyagawa Y, Takemura N. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs. J Vet Cardiol. 2016 Sep;18(3):248-54. doi: 10.1016/j.jvc.2016.05.001. PubMed PMID: 27364087. 2: Sugimoto K, Fujii Y, Takubo I, Shiga T, Sunahara H, Aoki T, Orito K. Pharmacodynamics of alacepril in healthy cats. J Feline Med Surg. 2016 Feb 29. pii: 1098612X16636420. [Epub ahead of print] PubMed PMID: 26927816. 3: Nonoguchi H, Kiyama S, Kitamura K, Naruse M, Tomita M, Tazoe N, Tajiri M, Nakayama Y, Kohda Y, Inoue T, Tomita K. Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure. Hypertens Res. 2008 Jan;31(1):29-36. doi: 10.1291/hypres.31.29. PubMed PMID: 18360015. 4: Katoh H, Itagaki T, Suzuki K, Obata Y, Adachi Y, Doi M, Sato S. [Successful extubation in a patient with alacepril-induced tongue angioedema]. Masui. 2010 Apr;59(4):519-22. Japanese. PubMed PMID: 20420150. 5: Usui S, Kubota M, Iguchi K, Kiho T, Sugiyama T, Katagiri Y, Hirano K. Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril. Pharm Res. 2003 Aug;20(8):1309-16. PubMed PMID: 12948030. 6: Shimozawa M, Naito Y, Manabe H, Uchiyama K, Katada K, Kuroda M, Nakabe N, Yoshida N, Yoshikawa T. The inhibitory effect of alacepril, an angiotensin-converting enzyme inhibitor, on endothelial inflammatory response induced by oxysterol and TNF-alpha. Redox Rep. 2004;9(6):354-9. PubMed PMID: 15720832. 7: Kinugawa T, Osaki S, Kato M, Ogino K, Shimoyama M, Tomikura Y, Igawa O, Hisatome I, Shigemasa C. Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure. Clin Exp Pharmacol Physiol. 2002 Dec;29(12):1060-5. PubMed PMID: 12390293. 8: Osaki S, Kinugawa T, Ogino K, Kato M, Furuse Y, Tomikura Y, Igawa O, Hisatome, Shigemasa C. Effects of acute and chronic alacepril treatment on exercise capacity and hemodynamics in patients with heart failure: a preliminary study. Int J Clin Pharmacol Ther. 2002 Feb;40(2):69-74. PubMed PMID: 11862975. 9: Atarashi K, Takagi M, Minami M, Ishiyama A. Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats. J Hypertens. 1999 Dec;17(12 Pt 2):1983-6. PubMed PMID: 10703899. 10: Miyazaki M, Takai S. Antiatherosclerotic effect of alacepril, an angiotensin-converting enzyme inhibitor, in monkeys fed a high-cholesterol diet. Hypertens Res. 1999 Mar;22(1):49-54. PubMed PMID: 10221351. 11: Kinugawa T, Kato M, Mori M, Endo A, Kato T, Hamada T, Noguchi N, Omodani H, Osaki S, Ogino K, Miyakoda H, Hisatome I, Shigemasa C. Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure. Eur J Clin Pharmacol. 1998 May;54(3):209-14. PubMed PMID: 9681661. 12: Nobuoka S, Nagashima J, Hatano S, Fujimaki R, Saito K, Tokuoka S, Ando H, Miyake F. Spatial and temporal analysis of left ventricular filling flow propagation in hypertensive patients before and after regression of myocardial hypertrophy with alacepril therapy. Echocardiography. 2001 Aug;18(6):479-83. PubMed PMID: 11567592. 13: Honda T, Hamada M, Shigematsu Y, Matsumoto Y, Matsuoka H, Hiwada K. Effect of antihypertensive therapy on aortic distensibility in patients with essential hypertension: comparison with trichlormethiazide, nicardipine and alacepril. Cardiovasc Drugs Ther. 1999 Jul;13(4):339-46. PubMed PMID: 10516870. 14: Noda Y, Mori A, Packer L. Free radical scavenging properties of alacepril metabolites and lisinopril. Res Commun Mol Pathol Pharmacol. 1997 May;96(2):125-36. PubMed PMID: 9226747. 15: Murohara T, Tayama S, Tabuchi T, Sumida H, Honda T, Hayasaki K, Yasue H. Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment. Am J Cardiol. 1996 Jun 1;77(14):1159-63. PubMed PMID: 8651088.